|
1
|
Zhu G, Azharuddin M, Islam R, Rahmoune H, Deb S, Kanji U, Das J, Osterrieth J, Aulakh P, Ibrahim-Hashi H, Manchanda R, Nilsson PH, Mollnes TE, Bhattacharyya M, Islam MM, Hinkula J, Slater NKH, Patra HK. Innate Immune Invisible Ultrasmall Gold Nanoparticles-Framework for Synthesis and Evaluation. ACS Appl Mater Interfaces 2021; 13:23410-23422. [PMID: 33978409 PMCID: PMC8289183 DOI: 10.1021/acsami.1c02834] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/12/2023]
Abstract
Nanomedicine is seen as a potential central player in the delivery of personalized medicine. Biocompatibility issues of nanoparticles have largely been resolved over the past decade. Despite their tremendous progress, less than 1% of applied nanosystems can hit their intended target location, such as a solid tumor, and this remains an obstacle to their full ability and potential with a high translational value. Therefore, achieving immune-tolerable, blood-compatible, and biofriendly nanoparticles remains an unmet need. The translational success of nanoformulations from bench to bedside involves a thorough assessment of their design, compatibility beyond cytotoxicity such as immune toxicity, blood compatibility, and immune-mediated destruction/rejection/clearance profile. Here, we report a one-pot process-engineered synthesis of ultrasmall gold nanoparticles (uGNPs) suitable for better body and renal clearance delivery of their payloads. We have obtained uGNP sizes of as low as 3 nm and have engineered the synthesis to allow them to be accurately sized (almost nanometer by nanometer). The synthesized uGNPs are biocompatible and can easily be functionalized to carry drugs, peptides, antibodies, and other therapeutic molecules. We have performed in vitro cell viability assays, immunotoxicity assays, inflammatory cytokine analysis, a complement activation study, and blood coagulation studies with the uGNPs to confirm their safety. These can help to set up a long-term safety-benefit framework of experimentation to reveal whether any designed nanoparticles are immune-tolerable and can be used as payload carriers for next-generation vaccines, chemotherapeutic drugs, and theranostic agents with better body clearance ability and deep tissue penetration.
Collapse
Affiliation(s)
- Geyunjian
Harry Zhu
- Department
of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge CB3 0AS, U.K.
| | - Mohammad Azharuddin
- Department
of Biomedical and Clinical Sciences (BKV), Linkoping University, Linkoping 581 83, Sweden
| | - Rakibul Islam
- Department
of Immunology, Oslo University Hospital, University of Oslo, Oslo 0372, Norway
| | - Hassan Rahmoune
- Department
of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge CB3 0AS, U.K.
| | - Suryyani Deb
- Department
of Biotechnology, Maulana Abul Kalam Azad
University of Technology (MAKAUT), Kolkata 700064, India
| | - Upasona Kanji
- Department
of Biotechnology, Maulana Abul Kalam Azad
University of Technology (MAKAUT), Kolkata 700064, India
| | - Jyotirmoy Das
- Department
of Biomedical and Clinical Sciences (BKV), Linkoping University, Linkoping 581 83, Sweden
| | - Johannes Osterrieth
- Department
of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge CB3 0AS, U.K.
| | - Parminder Aulakh
- Institute
for Manufacturing (IfM), University of Cambridge, Cambridge CB3 0FS, U.K.
| | - Hashi Ibrahim-Hashi
- Department
of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge CB3 0AS, U.K.
| | - Raghav Manchanda
- Department
of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge CB3 0AS, U.K.
| | - Per H. Nilsson
- Department
of Immunology, Oslo University Hospital, University of Oslo, Oslo 0372, Norway
- Linnaeus
Center for Biomaterials Chemistry, Linnaeus
University, Kalmar 391 82, Sweden
| | - Tom Eirik Mollnes
- Department
of Immunology, Oslo University Hospital, University of Oslo, Oslo 0372, Norway
- Research
Laboratory, Nordland Hospital, Bodø, and Faculty of Health Sciences,
K.G. Jebsen TREC, University of Tromsø, Tromsø 9037, Norway
| | - Maitreyee Bhattacharyya
- Institute
of Haematology and Transfusion Medicine, Calcutta Medical College, Calcutta 700073, India
| | - Mohammad M. Islam
- Massachusetts
Eye and Ear and Schepens Eye Research Institute, Dept of Ophthalmology, Harvard Medical School, Boston, Massachusetts 02114, United States
| | - Jorma Hinkula
- Department
of Biomedical and Clinical Sciences (BKV), Linkoping University, Linkoping 581 83, Sweden
| | - Nigel K. H. Slater
- Department
of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge CB3 0AS, U.K.
| | - Hirak K. Patra
- Department
of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge CB3 0AS, U.K.
- Department
of Surgical Biotechnology, University College
London (UCL), London NW3 2PF, U.K.
| |
Collapse
|